Literature DB >> 15318106

Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis.

Etsuko Hashimoto1, Makiko Taniai, Hiroyuki Kaneda, Katsutoshi Tokushige, Kiyoshi Hasegawa, Hiroaki Okuda, Keiko Shiratori, Ken Takasaki.   

Abstract

BACKGROUND: Alcoholic hepatitis and nonalcoholic steatohepatitis (NASH) show different clinical features with similar liver histology, but both disorders may progress to cirrhosis and hepatocellular carcinoma (HCC). HCC arising in alcoholic liver disease (ALD) or NASH, without hepatitis B or C virus infection, has been a rare observation, and there are no studies comparing the characteristics of ALD and NASH patients with HCC. Therefore, we compared the characteristics of ALD and NASH patients with HCC.
METHODS: A total of 1202 patients received a diagnosis of HCC at Tokyo Women's Medical University from 1989 to 2003, and their clinical data were collected prospectively. A clinical diagnosis was made to diagnose ALD, and clinical and histological changes were required to diagnose NASH. Of these patients, 88 received a diagnosis of HCC arising from ALD. Among them, a biopsy specimen was obtained in 50 patients (ALD-HCC group). We compared the clinical and histological characteristics of 50 ALD and 8 NASH patients (NASH-HCC group) associated with HCC. They all were negative for hepatitis virus infection by serological methods.
RESULTS: The most significant difference between these groups was sex. Women were significantly more common in the NASH-HCC group (6% vs. 63%; p < 0.0001). The median age was 65 years in the ALD-HCC group and 68 years in the NASH-HCC group. The risk factors for NASH all were high in the NASH-HCC group. However, liver function tests were similar in these groups. In the ALD-HCC group, 46 (92%) patients showed severe fibrosis; 2 had septal fibrosis and 44 had cirrhosis. All patients in the NASH-HCC group showed severe fibrosis, and seven had cirrhosis.
CONCLUSIONS: Severe fibrosis might be an important risk factor for HCC. Patients who have ALD or NASH with cirrhosis may develop HCC. This seems to occur in a sufficient number of cases to warrant regular screening for this complication.

Entities:  

Mesh:

Year:  2004        PMID: 15318106     DOI: 10.1097/01.alc.0000133547.70803.83

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  13 in total

Review 1.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

3.  Risk factors for liver disease and associated knowledge and practices among Mexican adults in the US and Mexico.

Authors:  Yvonne N Flores; Cathy M Lang; Jorge Salmerón; Roshan Bastani
Journal:  J Community Health       Date:  2012-04

4.  Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.

Authors:  Ali Zarrinpar; Claire M Faltermeier; Vatche G Agopian; Bita V Naini; Michael P Harlander-Locke; Fady M Kaldas; Douglas G Farmer; Ronald W Busuttil
Journal:  Liver Int       Date:  2018-12-02       Impact factor: 5.828

5.  Epidemiology of primary and secondary liver cancers.

Authors:  Ashwin Ananthakrishnan; Veena Gogineni; Kia Saeian
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

6.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Etsuko Hashimoto; Satoru Yatsuji; Maki Tobari; Makiko Taniai; Nobuyuki Torii; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

Review 8.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

9.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.

Authors:  Ledu Zhou; Yun Huang; Jingdong Li; Zhiming Wang
Journal:  Med Oncol       Date:  2009-03-20       Impact factor: 3.064

10.  Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study.

Authors:  Mohammad Inamul Haq; Thomas M Drake; Tee Lin Goh; Asma Ahmed; Ewan Forrest; Stephen Barclay; Ruth Gillespie; Mathew Priest; Jeff Evans; Janet Graham; Stuart Ballantyne; Donald C McMillan; Peter C Hayes; Thomas G Bird; Adrian J Stanley
Journal:  J Clin Med       Date:  2021-06-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.